JP2024501121A5 - - Google Patents
Info
- Publication number
- JP2024501121A5 JP2024501121A5 JP2023531534A JP2023531534A JP2024501121A5 JP 2024501121 A5 JP2024501121 A5 JP 2024501121A5 JP 2023531534 A JP2023531534 A JP 2023531534A JP 2023531534 A JP2023531534 A JP 2023531534A JP 2024501121 A5 JP2024501121 A5 JP 2024501121A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- acid sequence
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118198P | 2020-11-25 | 2020-11-25 | |
| US63/118,198 | 2020-11-25 | ||
| US202163229589P | 2021-08-05 | 2021-08-05 | |
| US63/229,589 | 2021-08-05 | ||
| PCT/EP2021/082872 WO2022112356A1 (en) | 2020-11-25 | 2021-11-24 | Treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024501121A JP2024501121A (ja) | 2024-01-11 |
| JP2024501121A5 true JP2024501121A5 (cg-RX-API-DMAC10.html) | 2024-11-29 |
Family
ID=78819544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531534A Pending JP2024501121A (ja) | 2020-11-25 | 2021-11-24 | 癌の処置 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240325557A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4251207A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2024501121A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230112656A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021387795A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3196198A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL302818A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2023005873A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2022112356A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114845740B (zh) | 2020-01-31 | 2026-06-02 | 先天制药公司 | 癌症的治疗 |
| EP4285935A1 (en) * | 2022-06-03 | 2023-12-06 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| JP2025519421A (ja) * | 2022-06-09 | 2025-06-26 | ベイジーン スイッツァランド ゲーエムベーハー | 抗体薬物複合体 |
| EP4309676A1 (en) * | 2022-07-22 | 2024-01-24 | Emergence Therapeutics AG | Novel anti-nectin-4 antibody camptothecin derivative conjugates |
| EP4593824A2 (en) * | 2022-09-28 | 2025-08-06 | Nuvation Bio Inc. | Anti-cancer nuclear hormone receptor-targeting compounds |
| EP4344707A1 (en) * | 2022-09-29 | 2024-04-03 | Emergence Therapeutics AG | New anti-nectin-4 antibody drug conjugates |
| KR20250079213A (ko) | 2022-10-09 | 2025-06-04 | 라노바 메디신즈 리미티드 | 화합물, 조성물 및 방법 |
| EP4534101A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| EP4534102A1 (en) | 2023-10-02 | 2025-04-09 | Eli Lilly and Company | Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload |
| KR20260113065A (ko) * | 2023-11-15 | 2026-07-21 | 머크 샤프 앤드 돔 엘엘씨 | 인간 넥틴-4 결합제 |
| KR20250177512A (ko) * | 2024-06-14 | 2025-12-24 | 삼성바이오에피스 주식회사 | 신규한 항-넥틴-4 항체 및 이의 용도 |
| US20260062472A1 (en) * | 2024-08-28 | 2026-03-05 | Earendil Labs Inc. | Bispecific antibody and use thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| WO1999061061A1 (fr) | 1998-05-22 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Composites medicamenteux |
| EP1243276A1 (en) | 2001-03-23 | 2002-09-25 | Franciscus Marinus Hendrikus De Groot | Elongated and multiple spacers containing activatible prodrugs |
| US7375234B2 (en) | 2002-05-30 | 2008-05-20 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| AU2003293666A1 (en) | 2002-11-11 | 2004-06-03 | Basf Aktiengesellschaft | Method for the production of 2-keto-l-gulonic acid-c4-c10 alkyl esters |
| WO2004043493A1 (en) | 2002-11-14 | 2004-05-27 | Syntarga B.V. | Prodrugs built as multiple self-elimination-release spacers |
| ES2605443T3 (es) | 2003-11-06 | 2017-03-14 | Seattle Genetics, Inc. | Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia |
| CA2556752C (en) | 2004-02-23 | 2016-02-02 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| ES2398975T3 (es) | 2004-03-01 | 2013-03-25 | Spirogen Sàrl | Derivados de 11-hidroxi-5H-pirrolo[2,1-c][1,4]benzodiazepin-5-ona como intermedios clave para la preparación de pirrolobenzodiazepinas sustituidas en C2 |
| US7807619B2 (en) | 2004-11-01 | 2010-10-05 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| ES2708763T3 (es) | 2005-07-07 | 2019-04-11 | Seattle Genetics Inc | Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| EP2907525B1 (en) | 2007-11-21 | 2018-05-16 | University Of Georgia Research Foundation, Inc. | Dibenzocyclooctene-compounds for bioorthogonal reactions |
| US20110301056A1 (en) * | 2008-12-12 | 2011-12-08 | Oncotherapy Science, Inc. | Nectin-4 for target genes of cancer therapy and diagnosis |
| FR2949469A1 (fr) | 2009-08-25 | 2011-03-04 | Sanofi Aventis | Derives anticancereux, leur preparation et leur application en therapeutique |
| WO2011121453A2 (en) | 2010-03-30 | 2011-10-06 | Clavis Pharma Asa | Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate |
| MX368648B (es) | 2010-04-15 | 2019-10-09 | Seattle Genetics Inc | Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas. |
| ES2874306T3 (es) | 2010-09-29 | 2021-11-04 | Agensys Inc | Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12 |
| SI2675480T1 (sl) | 2011-02-15 | 2019-05-31 | Immunogen, Inc. | Metode priprave konjugatov |
| CA2858806A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of polypeptides |
| WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| WO2014202773A1 (en) | 2013-06-20 | 2014-12-24 | Innate Pharma | Enzymatic conjugation of polypeptides |
| PT3057585T (pt) | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| EP3733209A1 (en) | 2014-10-03 | 2020-11-04 | Synaffix B.V. | Sulfamide linker, conjugates thereof, and methods of preparation |
| ES2885854T3 (es) | 2014-10-14 | 2021-12-15 | Polytherics Ltd | Proceso para la conjugación de un péptido o proteína con un reactivo que comprende un grupo saliente que incluye una porción de PEG |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| TWI870338B (zh) * | 2017-06-05 | 2025-01-21 | 美商艾澤西公司 | 粘附分子-4結合蛋白及其使用方法 |
| EP3700577A1 (en) | 2017-10-23 | 2020-09-02 | Mablink Bioscience | Ligand-drug-conjugate comprising a single molecular weight polysarcosine |
| CN113613679A (zh) | 2019-03-19 | 2021-11-05 | 保罗·谢勒学院 | 基于甘氨酸的接头的转谷氨酰胺酶缀合方法 |
| AU2020364959B2 (en) * | 2019-10-07 | 2026-07-09 | Centre National De La Recherche Scientifique - Cnrs - | Antibodies having specificity for Nectin-4 and uses thereof |
| CN112646038B (zh) * | 2019-10-11 | 2025-06-03 | 迈威(上海)生物科技股份有限公司 | 抗人Trop-2抗体及其应用 |
| US20230025600A1 (en) * | 2019-11-25 | 2023-01-26 | Agensys, Inc. | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins |
| CN114845740B (zh) * | 2020-01-31 | 2026-06-02 | 先天制药公司 | 癌症的治疗 |
| CN113527486B (zh) * | 2020-04-21 | 2025-12-02 | 迈威(上海)生物科技股份有限公司 | 一种抗Nectin-4的抗体及其应用 |
| IL298903A (en) * | 2020-06-18 | 2023-02-01 | Bioatla Llc | Antibodies against nectin-4 are conditionally active |
| US20230270871A1 (en) * | 2020-06-19 | 2023-08-31 | Agensys, Inc. | Markers for use in methods for treating cancers with antibody drug conjugates (adc) |
-
2021
- 2021-11-24 JP JP2023531534A patent/JP2024501121A/ja active Pending
- 2021-11-24 KR KR1020237019929A patent/KR20230112656A/ko active Pending
- 2021-11-24 IL IL302818A patent/IL302818A/en unknown
- 2021-11-24 US US18/038,723 patent/US20240325557A1/en active Pending
- 2021-11-24 AU AU2021387795A patent/AU2021387795A1/en active Pending
- 2021-11-24 WO PCT/EP2021/082872 patent/WO2022112356A1/en not_active Ceased
- 2021-11-24 EP EP21816063.8A patent/EP4251207A1/en active Pending
- 2021-11-24 MX MX2023005873A patent/MX2023005873A/es unknown
- 2021-11-24 CA CA3196198A patent/CA3196198A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7377327B2 (ja) | Ｂｃｍａモノクローナル抗体薬剤コンジュゲート | |
| JP7696635B2 (ja) | 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート | |
| JP2023522229A5 (cg-RX-API-DMAC10.html) | ||
| EP4087613A1 (en) | Anti-slc34a2 antibodies, antibody drug conjugates, and methods of use thereof | |
| TWI549968B (zh) | 抗體-藥物共軛體 | |
| CN114222752B (zh) | 抗组织因子抗体-药物缀合物及相关方法 | |
| JP2023520930A (ja) | 電荷多様性リンカー | |
| JP2019536740A5 (cg-RX-API-DMAC10.html) | ||
| JP2018127469A5 (cg-RX-API-DMAC10.html) | ||
| JP2017535246A5 (cg-RX-API-DMAC10.html) | ||
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| HRP20220172T1 (hr) | Protutijela protiv cd71 koja se mogu aktivirati, te postupci njihove uporabe | |
| JP2018520092A5 (cg-RX-API-DMAC10.html) | ||
| JP2016531914A5 (cg-RX-API-DMAC10.html) | ||
| CA2519113A1 (en) | Antibodies against insulin-like growth factor i receptor and uses thereof | |
| TWI845724B (zh) | 用於偶聯的多肽複合物及其應用 | |
| WO2024235136A9 (zh) | 杂环类化合物及其制备方法和用途 | |
| EP3675907A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
| CA3162282A1 (en) | Treatment of cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins | |
| JP2025513721A5 (cg-RX-API-DMAC10.html) | ||
| EP3675908A1 (en) | Anti-egfr antibody drug conjugates (adc) and uses thereof | |
| JP2015529656A (ja) | 抗ｅｔｂｒ抗体および免疫複合体 | |
| JPWO2021251459A5 (cg-RX-API-DMAC10.html) | ||
| JP2023506158A5 (cg-RX-API-DMAC10.html) | ||
| KR20240150773A (ko) | 항체 및 약물 접합체 및 이의 용도 |